Group 1 - The core indices related to the Hong Kong and A-share pharmaceutical sectors have shown significant increases, with the CSI Hong Kong Stock Connect Healthcare Index rising by 5.1%, the Hang Seng Stock Connect Innovative Drug Index by 4.8%, the CSI Innovative Drug Industry Index by 4.6%, the CSI Biotechnology Theme Index by 4%, and the CSI 300 Healthcare Index by 3.6% [1][5][9][13][15] - The Hang Seng Innovative Drug ETF (159316) has seen continuous capital inflow for four consecutive trading days, with its latest scale exceeding 1.8 billion yuan, marking a historical high [1] Group 2 - The CSI Hong Kong Stock Connect Healthcare Index focuses on leading stocks in the Hong Kong healthcare sector, comprising 50 stocks from medical devices, biopharmaceuticals, chemical drugs, and other healthcare-related companies [3] - The CSI Innovative Drug Industry Index targets leading innovative drug companies in the A-share market, consisting of no more than 50 stocks involved in innovative drug research and development [7] - The CSI Biotechnology Theme Index centers on leading biotechnology companies in the A-share market, including no more than 50 stocks related to gene diagnosis, biopharmaceuticals, blood products, and other human biotechnology [11] - The CSI 300 Healthcare Index encompasses leading companies in the A-share healthcare sector, covering chemical pharmaceuticals, medical services, medical devices, and other segments of the future health industry [15]

Group 1 - The core viewpoint of the news highlights the performance of various healthcare indices, with the CSI Hong Kong Stock Connect Healthcare Index rising by 2%, the CSI 300 Healthcare Index increasing by 1.7%, and the Hang Seng Hong Kong Stock Connect Innovative Drug Index up by 1.5% [1][4][11] - The CSI Hong Kong Stock Connect Healthcare Index focuses on leading companies in the Hong Kong healthcare sector, comprising 50 stocks from medical devices, biopharmaceuticals, chemical drugs, and other healthcare-related industries [3] - The CSI Innovative Drug Industry Index targets leading A-share innovative drug companies, consisting of no more than 50 stocks involved in innovative drug research and development [6] - The CSI Biotechnology Theme Index centers on leading A-share biotechnology companies, including no more than 50 stocks related to gene diagnostics, biopharmaceuticals, blood products, and other human biotechnology [8] - The CSI 300 Healthcare Index encompasses leading A-share healthcare companies, covering segments such as chemical pharmaceuticals, medical services, and medical devices [10]